About
Pressroom
Resources
Get Updates
Issues
Access to Medicines
Funding the Fight
Health Justice
Transparency & Accountability
PEPFAR Watch
Blog
Our Impact
Take Action
Do something now
DONATE
Access to Medicines
Access to Medicines
Guia do ativista dia mundial de luta contra aids 2024: Acesso global ao lenacapa...
Access to Medicines
World AIDS Day Activist Toolkit: Global Access to Generic Lenacapavir Now!
Access to Medicines
Expanding Frontiers for Compulsory Licensing
Access to Medicines
Supporting Equitable Access to Medicines in the WHO Pandemic Agreement
Access to Medicines
Letter to Procurement Agents: Say No to Secrecy in Medical Product Agreements
Access to Medicines
Special 301 Review Comment
Access to Medicines
Comment Re: Implications of Access and Benefit Sharing Commitments/Regimes and O...
Access to Medicines
The Big Pharma Bullies: Secrecy for Vaccine Supplies in a Pandemic
Access to Medicines
Hearing Testimony: COVID-19 Diagnostics and Therapeutics, Supply, Demand, and TR...
Access to Medicines
COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexi...
Access to Medicines
TRIPS-Compliant Alternatives for Overcoming Intellectual Property Barriers to CO...
Access to Medicines
Letter to ViiV re CAB-LA for PrEP
Access to Medicines
BMJ Global Health: A pandemic treaty for equitable global access to medical coun...
Access to Medicines
Letter to Pres. Biden on COVID19 Global Summit May 2022
Access to Medicines
Amicus Brief on Human Rights Principles and TRIPS-Compliant Interpretation to th...
Access to Medicines
Policy Brief: Community-Based COVID-19 Test-and-Treat (April 2022)
Access to Medicines
Community-Based Test-and-Treat
Access to Medicines
To Save Lives, a COVID Intellectual Property Waiver Must Cover Medicines and Oth...
Access to Medicines
Request of Least Developed Countries for Extension of Transition Period
Access to Medicines
Policy Brief: Third-Way Proposals from Big Pharma and the WTO are the Same-Old W...